NR4A1 and breast cancer: In a study on hormone receptor‐positive early‐stage breast cancer, ABC was administered more often to young patients (40% of the patients <65 years), to the ones with stage III disease (69%) or higher 21‐gene recurrence scores, and positive lymph nodes encouraged the selection of ABC in the absence of high recurrence scores.9